Trial Profile
Relative Bioavailability, Safety, and Tolerability Following Subcutaneous Injection of Different Doses of BI 655130 and Different Injection Sites in Healthy Male and Female Subjects (a Single Dose, Mono-centric, Open-label Study in Matched-group Design)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Spesolimab (Primary)
- Indications Atopic dermatitis; Crohn's disease; Palmoplantar pustulosis; Pustular psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 01 Dec 2022 Results from Phase I Clinical Studies ( NCT02525679, NCT02852824, NCT03100903, NCT03123094, NCT03617835 ) assessing pharmacokinetics of spesolimab and evaluate changes with respect to dose, frequency of dosing, formulation and injection site. Immunogenicity, safety and tolerability published in the Clinical Pharmacokinetics
- 06 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Planned End Date changed from 27 May 2019 to 5 Jun 2019.